Giant $7.2 Billion Acquisition Validates CBD
With Jazz Pharmaceuticals announcing they plan to acquire GW Pharmaceuticals for USD$7.2 billion, the pharma industry just validated a revolutionary treatment.
Banking expert Jason Wilson of ETF Managers Group reported, “The deal is a clear sign that the pharmaceutical industry is recognizing the value and future potential of cannabinoid-based medicines.”
David Johnson, CEO of another biotech company stated the deal “serves as further validation that thoroughly researched and developed medical cannabinoids have significant potential to address patients’ unmet medical needs.”
This is groundbreaking news for companies working with cannabidiol (CBD) as an innovative treatment…
Just as GW Pharmaceuticals did before Jazz Pharmaceuticals announced plans to acquire them for USD$7.2 billion.
But it could be even bigger for one company who hopes to tap the power of this treatment to address the biggest health issue in the world.
After COVID-19 claimed roughly 2.4 million lives over the last year, we’re still scrambling to get a handle on the virus that has wreaked havoc worldwide.
And while the mortality rate is estimated at somewhere between 1-2% in the general population, the disease can be much more dangerous for one group in particular.
For those with a history of cardiovascular issues, the survival rate plummets to nearly 50%.
That’s because when the immune system revs up to tackle the virus head-on, it can often trigger a “cytokine storm,” which can mean more inflammation and damage to the heart and lungs…
And for those who already have a history of cardiovascular issues, COVID-19 can cause deadly complications with organs not working at full strength.
But Cardiol Therapeutics may have a solution that could help save lives around the world.
And it’s their own trademarked version of the same CBD molecule that led to the multi-billion acquisition.
In extensive pre-clinical investigations by Cardiol and others, they discovered that CBD has impressive anti-inflammatory effects for the heart…
Which suggests it may be exactly the type of breakthrough treatment needed to protect the most vulnerable to COVID-19’s deadly effects.
They’ve been given the green light from the FDA to begin a Phase II/Phase III trial for their oral CBD formulation, CardiolRx™.
This is incredibly promising news for Cardiol, which has seen their shares soar 150% in the last 6 months.
Any news of positive results as the trial progresses could become a major catalyst and catch the attention of large pharmaceutical companies on the hunt for their next big acquisition.
Take GW Pharmaceuticals, for example. After developing their CBD treatment, Epidiolex, a few years ago, they started receiving attention from major players in the sector.
And today, they’re looking at an incredible USD$7.2 billion payday, all in just a few short years.
But there’s a reason why Cardiol’s treatment could be even bigger than GW Pharmaceuticals’ treatment if all goes according to plan.
Read Our Exclusive Report To Learn How Cardiol Could Benefit From The CBD Industry’s Latest USD$7.2 Billion Acquisition
Millions Affected Every Year
While Cardiol is making news for their upcoming trial using CardiolRx™ to treat COVID-19, they’ve been working to help those with other major cardiovascular issues for years.
And their pipeline shows two more ways that CardiolRx™ could soon change lives.
First, they’re planning to file with the FDA to begin a Phase II international trial for acute myocarditis, the most common cause of sudden cardiac death in people under age 35.
If results of this trial are positive, it could not only deliver hope to up to 73,000 young Americans, it could also provide a major opportunity for Cardiol through the FDA’s Orphan Drug Designation program.
The FDA grants an orphan drug status to pharmaceuticals being developed to treat medical conditions affecting fewer than 200,000 people.
And going down this path has helped a number of small biotech companies turn into billion-dollar giants in a very short window of time.
This was a key piece of what helped GW Pharmaceuticals start their way toward their multi-billion dollar acquisition, as they treated two rare forms of childhood epilepsy.
But with acute myocarditis, Cardiol is aiming to treat a patient group that’s twice the size of these rare epilepsy markets.
And they’re hopeful in their prospects in upcoming trials as past research has already shown the dramatic effects of this molecule.
But as they’ve been preparing the massive COVID-19 and acute myocarditis trials, they’ve also been making waves in another major market: chronic heart failure.
As the single biggest cause of hospitalizations in the U.S., it affects over 6 million adults in North America. And sadly, 30% of patients with heart failure die within 1 year.
Over the last 20 years, there’s been little to no meaningful development in treatments for diastolic heart failure.
But Cardiol has been developing a proprietary subcutaneous formulation of CardiolRx™, administered in a similar fashion to insulin for diabetes.
This would be a completely new way of treating chronic heart failure…
And just as it could help those with cardiovascular issues with COVID-19, it’s based on CBD’s ability to treat inflamed heart tissue and treat fibrosis (scarring) in heart muscle.
It may be the breakthrough that millions of people have been waiting for, and it could have tremendous implications for this enormous market.
But beyond the upcoming trials for these 3 diseases, Cardiol has discovered another way to drive revenue thanks to a new partnership in Canada.
Many providers are demanding a cannabidiol solution that does not contain THC, the active psychoactive ingredient in cannabis.
Cardiol responded to this hole in the market by producing the purest form of an oral cannabidiol formulation to date, Cortalex™.
They have partnered with Shoppers Drug Mart, the largest pharmacy chain in Canada, with over 1,300 stores, to supply it through their online portal.
This gives Cardiol the chance to add revenue while at the same time doing groundbreaking work with their upcoming clinical trials.
If all goes according to plan, Cardiol’s revolutionary treatment, CardiolRx™ could be a game-changer, both for patients and investors.
Just 4 years ago, another small company, MyoKardia, began developing a treatment for a rare cardiac disease.
At that time, they were valued at around USD$200 million. But in September, Bristol-Myers acquired them in a deal worth USD$13 billion.
That’s the power of delivering an effective treatment for rare cardiac diseases.
Any positive news could be a major catalyst for Cardiol and their early investors.
Read Our Exclusive Report On How Investors Could Profit From Cardiol’s Important Clinical Trials In 2021
IMPORTANT NOTICE AND DISCLAIMER
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.